Takeda officer sells ADSs for tax withholding

Takeda Pharmaceutical Co Ltd executive Gabriele Ricci, Chief Data & Tech.

Rhea-AI Filing Summary

Takeda Pharmaceutical Co Ltd executive Gabriele Ricci, Chief Data & Tech. Officer, reported a sale of 25,088 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards, and Ricci now directly holds 171,654 ADSs.

Insider Trade Summary

Net Seller: 25,088 shares

Net Sell 1 txn

Insider Ricci Gabriele

Role Chief Data & Tech. Officer

Sold 25,088 shs ($429K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	25,088	$17.10	$429K

Holdings After Transaction: American Depositary Shares — 171,654 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 25,088 American Depositary Shares Weighted average sale price: $17.10 per ADS Shares held after transaction: 171,654 American Depositary Shares

3 metrics

Shares sold 25,088 American Depositary Shares Non-derivative sale on 2026-08-10 to cover taxes on vesting awards

Weighted average sale price $17.10 per ADS Price for the 25,088 ADSs sold, based on multiple trades

Shares held after transaction 171,654 American Depositary Shares Direct ownership reported following the 2026-08-10 sale

Key Terms

American Depositary Shares, mandatory sale to cover taxes, weighted average price

3 terms

American Depositary Shares financial

"Represents 25,088 American Depositary Shares sold by the reporting person"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory sale to cover taxes financial

"Represents a mandatory sale to cover taxes associated with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Takeda (TAK) report for Gabriele Ricci?

Takeda reported that Chief Data & Tech. Officer Gabriele Ricci sold 25,088 American Depositary Shares on 2026-08-10. The sale was connected to tax obligations on vesting equity awards.

How many Takeda (TAK) ADSs did Gabriele Ricci sell and at what price?

Gabriele Ricci sold 25,088 ADSs at a weighted average price of $17.10 per ADS. A footnote states the price reflects multiple trades within a range, available upon request.

Why did Takeda (TAK) officer Gabriele Ricci sell 25,088 ADSs?

The filing states the transaction was a mandatory sale to cover taxes associated with the vesting of equity awards held by Gabriele Ricci, rather than a discretionary open-market sale.

How many Takeda (TAK) ADSs does Gabriele Ricci hold after the reported sale?

After the 25,088-ADS sale, Gabriele Ricci directly holds 171,654 American Depositary Shares of Takeda Pharmaceutical Co Ltd, according to the reported post-transaction ownership figure.

Was the Takeda (TAK) insider sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction. Instead, a footnote describes the sale as mandatory tax-related due to vesting equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 09:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ricci Gabriele

(Last) (First) (Middle)

650 E. KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Data & Tech. Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		25,088	D	$17.1(2)	171,654	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Gabriele Ricci	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)